Immunis is a clinical-stage biotechnology company developing stem cell‑derived, multi-active biologics using its multi-active secretome technology to deliver natural human immune modulators. Its lead investigational product, IMM01‑STEM, is being developed to address age-related muscle atrophy and metabolic dysfunction in elderly patients. A Phase 1/2a trial in nine elderly patients showed safety, tolerability and suggestive efficacy, including improvements in quality-of-life measures and gait speed. Preclinical studies in aged mouse models published in GeroScience and Aging Cell showed reversal of muscle atrophy, improved muscle function, enhanced metabolism and reduced body and liver fat. The company describes itself as the leading biotech with the most advanced stem cell‑derived multi-active biologic in human clinical trials. The recently closed financing will fund two Phase 2 clinical trials to further test IMM01‑STEM’s efficacy in targeted elderly populations. Immunis is a private biotech developing a novel immunomodulatory secretome product line (STEM) to address age- and disease-related immune decline. The STEM product line leverages stem cell technology to deliver all-natural, all-human immune modulators in their natural, relative physiological concentrations. Its lead secretome treatment, IMM01-STEM, is described as using natural immunomodulators with potent cytoskeletal remodeling properties. The company plans to use the new funding to support clinical assessment of IMM01-STEM in an FDA-awarded Phase 1/2a clinical trial targeting muscle atrophy. The trial targets muscle atrophy, a condition the article states is experienced by 100% of the population in age, disuse, and disease contexts. Immunis is based in Irvine, California.

Total raised

$35M

Funding rounds

2

Latest round

Series A

Latest activity

Jan 2025